# SUBpectoral Local anaesthetic Infusion following MastEctomy - version 1 (SUBLIME)

Submission date	Recruitment status	[X] Prospectively registered		
05/09/2012	No longer recruiting  Overall study status	[X] Protocol		
Registration date		Statistical analysis plan		
10/09/2012 Last Edited	Completed  Condition category	Results		
		Individual participant data		
29/05/2019	Cancer	Record updated in last year		

# Plain English summary of protocol

http://www.cancerresearchuk.org/cancer-help/trials/a-trial-looking-extra-type-pain-control-after-surgery-remove-your-breast-sublime

# Contact information

# Type(s)

Scientific

#### Contact name

Ms Sarah Campbell

#### Contact details

Peninsula Clinical Trials Unit Room N16 ITTC Building 1 Plymouth Science Park Davy Road Plymouth United Kingdom PL6 8BX +44 (0)1752 430 392 sarah.campbell@plymouth.ac.uk

# Additional identifiers

Clinical Trials Information System (CTIS)

2011-005775-16

#### Protocol serial number

12964

# Study information

#### Scientific Title

A randomised, double blind, placebo-controlled trial of continuous subpectoral local anaesthetic infusion for pain and shoulder function following mastectomy

#### Acronym

SUBLIME v1

## **Study objectives**

The aim of the study is to establish whether the use of continuous local anaesthetic infusion in the sub-pectoral tissue plane can improve post-operative analgesia and quality of life for patients undergoing mastectomy with or without axillary surgery.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

First MREC, 06/06/2012, ref: 12/SW/0149

## Study design

Randomised interventional trial

## Primary study design

Interventional

# Study type(s)

Treatment

# Health condition(s) or problem(s) studied

Breast Cancer

#### **Interventions**

Participants will be randomised to receive 0.25% levobupivacaine or placebo (0.9% saline) by subpectoral infusion for 24 hours and will be followed up at 24 hours, 14 days and six months postoperatively.

# Intervention Type

Drug

#### Phase

Not Applicable

# Drug/device/biological/vaccine name(s)

Levobupivacaine

# Primary outcome(s)

Total morphine consumption, measured during the first 24 hours post-operatively

# Key secondary outcome(s))

Total pain, measured using the Visual Analog Scale for Pain (VAS Pain) in the first 24 hours postoperatively

# Completion date

14/08/2016

# **Eligibility**

#### Key inclusion criteria

- 1. All women presenting for unilateral mastectomy surgery at the Royal Cornwall Hospitals NHS Trust and Royal Devon and Exeter NHS Foundation Trust
- 2. Female
- 3. Aged 18 years and over
- 4. Scheduled for unilateral mastectomy with or without axillary involvement

# Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

Adult

# Lower age limit

18 years

#### Sex

Female

### Key exclusion criteria

- 1. Inability to give informed consent
- 2. Primary reconstructive surgery
- 3. Hypotension, hypovolaemia or any form of shock
- 4. Known allergy or sensitivity to local anaesthetic agents, morphine, paracetamol or ondansetron
- 5. Pregnancy
- 6. Daily opioid analgesic use
- 7. Inability to understand or use a PCA device
- 8. Inability to understand or complete the visual analogue assessment tools
- 9. Concurrent participation in another interventional study that might conflict with this trial

## Date of first enrolment

06/12/2012

#### Date of final enrolment

28/07/2015

# Locations

#### Countries of recruitment

United Kingdom

England

Study participating centre Royal Cornwall Hospitals NHS Trust

Truro United Kingdom TR1 3LJ

Study participating centre
York Teaching Hospital NHS Foundation Trust
York
United Kingdom
YO31 8HE

# Sponsor information

# Organisation

Royal Cornwall Hospitals NHS Trust (UK)

#### **ROR**

https://ror.org/026xdcm93

# Funder(s)

#### Funder type

Government

#### **Funder Name**

National Institute for Health Research (ref: PB-PG-0610-22342)

#### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

## **Funding Body Type**

Government organisation

# Funding Body Subtype

National government

# Location

United Kingdom

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>	protocol	30/09/2014		Yes	No
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes